Malini Marion Gandhi, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 4 | 2024 | 1579 | 0.720 |
Why?
|
| Hepatitis C, Chronic | 3 | 2023 | 1018 | 0.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 5319 | 0.480 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 13382 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2024 | 571 | 0.350 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 95 | 0.210 |
Why?
|
| Indazoles | 1 | 2024 | 304 | 0.210 |
Why?
|
| HIV Infections | 3 | 2023 | 17337 | 0.190 |
Why?
|
| Hepacivirus | 3 | 2024 | 1330 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2023 | 225 | 0.190 |
Why?
|
| Antiviral Agents | 3 | 2023 | 3039 | 0.180 |
Why?
|
| Laboratories | 1 | 2024 | 458 | 0.170 |
Why?
|
| Point Mutation | 1 | 2024 | 1595 | 0.160 |
Why?
|
| Benzamides | 1 | 2024 | 1371 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 2425 | 0.120 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 2379 | 0.110 |
Why?
|
| Myanmar | 2 | 2024 | 43 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 4512 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 5672 | 0.090 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 624 | 0.090 |
Why?
|
| Aneuploidy | 2 | 2023 | 552 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 5304 | 0.080 |
Why?
|
| Lysosomes | 1 | 2013 | 924 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2013 | 1250 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 1835 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 2189 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9277 | 0.060 |
Why?
|
| Inflammation | 1 | 2023 | 10760 | 0.060 |
Why?
|
| Mutation | 2 | 2023 | 30016 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 373 | 0.050 |
Why?
|
| Chromosomes | 1 | 2023 | 578 | 0.040 |
Why?
|
| Humans | 12 | 2024 | 760617 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2024 | 1125 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 54360 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2024 | 1865 | 0.040 |
Why?
|
| Genomics | 2 | 2024 | 5822 | 0.040 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2023 | 1768 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2024 | 2838 | 0.030 |
Why?
|
| Viral Load | 1 | 2024 | 3325 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2023 | 2570 | 0.030 |
Why?
|
| Cathepsins | 1 | 2013 | 241 | 0.030 |
Why?
|
| Male | 3 | 2024 | 360358 | 0.020 |
Why?
|
| Aged | 1 | 2023 | 169042 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3868 | 0.020 |
Why?
|
| Adult | 1 | 2023 | 220969 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 2495 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 14648 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 1441 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 16967 | 0.020 |
Why?
|
| Logistic Models | 1 | 2020 | 13245 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 64568 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 13441 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 17629 | 0.010 |
Why?
|
| Female | 3 | 2024 | 392148 | 0.010 |
Why?
|
| Proteins | 1 | 2013 | 6030 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2013 | 18937 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81368 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2023 | 80566 | 0.010 |
Why?
|
| United States | 1 | 2020 | 72272 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 168201 | 0.010 |
Why?
|